Curis is a biotechnology business based in the US. Curis shares (CRIS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.70 – a decrease of 5.85% over the previous week. Curis employs 49 staff and has a trailing 12-month revenue of around $10.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.70 |
|---|---|
| 52-week range | $3.51 - $17.49 |
| 50-day moving average | $5.01 |
| 200-day moving average | $8.52 |
| Wall St. target price | $21.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-8.17 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.79 from 2024-11-19
| 1 week (2024-11-13) | -3.56% |
|---|---|
| 1 month (2024-10-18) | -28.36% |
| 3 months (2024-08-20) | -13.86% |
| 6 months (2024-05-20) | -63.97% |
| 1 year (2023-11-20) | -55.20% |
|---|---|
| 2 years (2022-11-18) | -77.98% |
| 3 years (2021-11-19) | 102.6 |
| 5 years (2019-11-20) | 30.6 |
| Revenue TTM | $10.2 million |
|---|---|
| Gross profit TTM | $-33,372,000 |
| Return on assets TTM | -45.97% |
| Return on equity TTM | -372.68% |
| Profit margin | 0% |
| Book value | $3.34 |
| Market Capitalization | $23.8 million |
TTM: trailing 12 months
We're not expecting Curis to pay a dividend over the next 12 months.
Curis's shares were split on a 1:5 basis on 29 May 2018 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Curis shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Curis shares which in turn could have impacted Curis's share price.
Over the last 12 months, Curis's shares have ranged in value from as little as $3.51 up to $17.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Curis's is 3.349. This would suggest that Curis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Curis, Inc. , a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc. , or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.